Cytokinetics (CYTK) CEO trims stake with 7,500-share stock sale

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Cytokinetics Inc. President and CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $77.21 per share. Following this sale, he holds 392,830 shares directly. Separate trust holdings reported as of the same date each hold 2,083 shares indirectly.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares ($579,075)

Net Sell 3 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($579K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,500	$77.21	$579K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 392,830 shares (Direct, null); Common Stock — 2,083 shares (Indirect, by Trust 1)

Footnotes (1)

Shares held by The Bridget Blum 2003 Irrevocable Trust. Shares held by The Brittany Blum 2003 Irrevocable Trust.

Key Figures

Shares sold: 7,500 shares Sale price: $77.21 per share Direct holdings after sale: 392,830 shares +2 more

5 metrics

Shares sold 7,500 shares Open-market sale of common stock on May 27, 2026

Sale price $77.21 per share Price for the 7,500-share common stock sale

Direct holdings after sale 392,830 shares Common stock directly owned by CEO after transaction

Trust 1 holdings 2,083 shares Common stock held by The Bridget Blum 2003 Irrevocable Trust

Trust 2 holdings 2,083 shares Common stock held by The Brittany Blum 2003 Irrevocable Trust

Key Terms

Form 4, open-market sale, indirect ownership, Irrevocable Trust

4 terms

Form 4 regulatory

"Insider transaction is reported on Form 4 for Cytokinetics."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market sale financial

"The 7,500-share transaction is classified as an open-market sale."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"Trust-held shares are disclosed as indirect ownership related to Robert Blum."

Irrevocable Trust financial

"Shares are held by The Bridget Blum 2003 Irrevocable Trust and a similar trust."

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

05/28/2026 - 04:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/27/2026		S		7,500	D	$77.21	392,830	D
Common Stock								2,083	I	by Trust 1⁽¹⁾
Common Stock								2,083	I	by Trust 2⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Cytokinetics (CYTK) CEO Robert Blum report in this Form 4?

Robert Blum reported an open-market sale of 7,500 shares of Cytokinetics common stock. The sale was executed at a price of $77.21 per share, and the transaction is classified as a non-derivative disposition of directly held common shares.

At what price did the Cytokinetics CEO sell his CYTK shares?

The CEO sold 7,500 Cytokinetics common shares at $77.21 per share. This reported price represents the transaction price for the non-derivative open-market sale disclosed as of May 27, 2026, in the Form 4 insider trading report.

How many Cytokinetics shares does the CEO hold after this reported sale?

After the reported transaction, Robert Blum directly holds 392,830 shares of Cytokinetics common stock. This figure reflects his direct ownership position following the 7,500-share open-market sale reported in the Form 4 filing for May 27, 2026.

Are there any indirect Cytokinetics holdings reported for the CEO in this Form 4?

Yes. The filing reports 2,083 Cytokinetics shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, both shown as indirect ownership positions associated with Robert Blum on the same date.

Does this Cytokinetics Form 4 show any option exercises or derivative transactions?

The Form 4 does not report any derivative transactions or option exercises. All reported activity involves common stock, with one non-derivative open-market sale and separate entries reflecting indirect common stock holdings in two irrevocable trusts as of the stated date.